Nidhi Aggarwal

Dr. Nidhi Aggarwal

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MCMycal Casey
Mycal Casey
LOLorriane Odhiambo
Lorriane Odhiambo
NANidhi Aggarwal
Nidhi Aggarwal
MSMahran Shoukier
Mahran Shoukier
JGJamani Garner
Jamani Garner
JCJorge Cortes
Jorge Cortes
PURPOSE: There are significant disparities in care and outcomes for patients with leukemias and multiple myeloma (MM). To evaluate the extent to which clinical trials (CTs) match the demographic and geographic diversity of populations affected by leukemias and MM. METHODS: CTs leading to drug approval were identified from the US Food and Drug Administration databases. Demographic and geographic data were collected from ClinicalTrials.gov and primary manuscripts. Standard descriptive statistics were used to summarize the data in frequencies and proportions, including 95% CIs, by race, ethnicity, sex, and malignancy subtypes. RESULTS: A total of 41 (67.2%) trials leading to drug approval reported data on race and 20 (48.8%) on ethnicity. These trials included 13,731 patients, of whom 11,209 (81.6%) were White. Among minorities, Asian-Pacific Islanders and Blacks had the highest representation in chronic myeloid leukemia, 147 (12.7%) and 61 (5.3%), and lowest in chronic lymphocytic leukemia, 55 (3%) and 20 (1.1%), respectively. Proportions for Blacks, Native Americans, and Hispanics were significantly low, reflecting under-representation in trials compared with the proportion in the general population. Females were also under-represented in acute myeloid leukemia (44.7% v 60.5%, P < .0001), and males in MM (55.3% v 60.2%, P < .0001) and chronic myeloid leukemia (55.2% v 62.9%, P < .0001). The geographic distribution of trials showed inadequate regional and state participation compared with mortality for all malignancies except MM. CONCLUSION: There are significant demographic and geographic under-representation and imbalances in pivotal CTs leading to drug approvals for leukemias and MM compared with the population affected. These disparities need to be addressed to make results applicable to all relevant populations.

5 January 2023 in Blood
Verified
Journal Article
Open access
PDF file
EGEmma M. Groarke
Emma M. Groarke
XFXingmin Feng
Xingmin Feng
NANidhi Aggarwal
Nidhi Aggarwal
AMAsh Lee Manley
Ash Lee Manley
ZWZhijie Wu
Zhijie Wu
NYNeal S. Young
Neal S. Young
Immune aplastic anemia (AA) is a severe blood disease characterized by T-lymphocyte− mediated stem cell destruction. Hematopoietic stem cell transplantation and immunosuppression are effective, but they entail costs and risks, and are not always successful. The Janus kinase (JAK) 1/2 inhibitor ruxolitinib (RUX) suppresses cytotoxic T-cell activation and inhibits cytokine production in models of graft-versus-host disease. We tested RUX in murine immune AA for potential therapeutic benefit. After infusion of lymph node (LN) cells mismatched at the major histocompatibility complex [C67BL/6 (B6)⇒CByB6F1], RUX, administered as a food additive (Rux-chow), attenuated bone marrow hypoplasia, ameliorated peripheral blood pancytopenia, preserved hematopoietic progenitors, and prevented mortality, when used either prophylactically or therapeutically. RUX suppressed the infiltration, proliferation, and activation of effector T cells in the bone marrow and mitigated Fas-mediated apoptotic destruction of target hematopoietic cells. Similar effects were obtained when Rux-chow was fed to C.B10 mice in a minor histocompatibility antigen mismatched (B6⇒C.B10) AA model. RUX only modestly suppressed lymphoid and erythroid hematopoiesis in normal and irradiated CByB6F1 mice. Our data support clinical trials of JAK/STAT inhibitors in human AA and other immune bone marrow failure syndromes.

6 April 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
NANidhi Aggarwal
Nidhi Aggarwal
AMAsh Lee Manley
Ash Lee Manley
RSRuba Shalhoub
Ruba Shalhoub
JDJibran Durrani
Jibran Durrani
OROlga Rios
Olga Rios
EGEmma M. Groarke
Emma M. Groarke

10 January 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
XFXingmin Feng
Xingmin Feng
JKJisoo Kim
Jisoo Kim
GGGladys Gonzalez-Matias
Gladys Gonzalez-Matias
NANidhi Aggarwal
Nidhi Aggarwal
AMAsh Lee Manley
Ash Lee Manley
NYNeal S. Young
Neal S. Young
Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that originate in the bone marrow (BM) and have immunoregulatory functions. MDSCs have been implicated in the pathogenesis of several autoimmune diseases but have not been investigated in immune aplastic anemia (AA). We examined the roles of granulocytic-MDSCs (G-MDSCs) in murine models of human AA and BM failure (BMF). As both prophylaxis and therapy, BM-derived G-MDSCs improved pancytopenia and BM cellularity and suppressed BM T-cell infiltration in major histocompatibility complex (MHC)-matched C.B10 BMF mice. These effects were not obtained in the MHC-mismatched CByB6F1 AA model, likely because of MHC disparity between G-MDSCs and donor T cells. Single-cell RNA sequencing demonstrated that G-MDSCs downregulated cell cycle–related genes in BM-infiltrated T cells, consistent with suppression of T-cell proliferation by G-MDSCs through reactive oxygen species pathways. Clearance of G-MDSCs in the MHC-mismatched CByB6F1 model using anti-Ly6G antibody facilitated T cell–mediated BM destruction, suggesting an intrinsic immunosuppressive property of G-MDSCs. However, the same anti-Ly6G antibody in the MHC-matched C.B10 AA model mildly mitigated BMF, associated with expansion of an intermediate Ly6G population. Our results demonstrate that G-MDSC eradication and therapeutic efficacy are immune context-dependent.

14 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MCMycal Casey
Mycal Casey
LOLorriane Odhiambo
Lorriane Odhiambo
NANidhi Aggarwal
Nidhi Aggarwal
MSMahran Shoukier
Mahran Shoukier
KIKM Monirul Islam
KM Monirul Islam
JCJorge Cortes
Jorge Cortes
Background: Evaluating clinical trial representation for countries with different socio-demographic index (SDI) and tyrosine kinase inhibitor (TKI) availability for chronic myeloid leukemia (CML). Methods: CML incidence rates (IRs) and disability-adjusted life years (DALYs) (1999–2019) from the Institute of Health Metrics and Evaluation were analyzed. Trials investigating TKI use in CML were obtained from ClinicalTrials.gov. Site data for eligible trials (N = 30) and DALYs were analyzed. TKI approvals, DALYs, and IRs were summarized by SDI. Results: North America (NA) had significant decreases in annual percent change (APC) in DALYs and incidence rates from 1999 to 2004. IRs were highest in Europe and Central Asia (ECA) and NA, while DALYs were highest in South Asia (SAsia) and Sub-Saharan Africa (SSA). Countries in the high-SDI quintile were likely to have lower DALYs than lower-SDI quintiles. Differences in regional DALYs vs. sites in TKI trials were significant for SAsia, SSA, and ECA. High-SDI countries were included in all 30 trials, and TKI approvals were prominent in high-SDI (142) vs. low-SDI (14) countries. Conclusions: The inclusion of disproportionately affected countries during the design of and recruitment into clinical trials should occur, as should TKI availability. The lack of representation demonstrates healthcare disparities.

8 August 2023 in HemaSphere
Verified
Journal Article
Open access
XFXingmin Feng
Xingmin Feng
JDJibran Durrani
Jibran Durrani
AMAsh Lee Manley
Ash Lee Manley
WZWu Zhijie
Wu Zhijie
NANidhi Aggarwal
Nidhi Aggarwal
YNYoung Neal
Young Neal